Potential uses of prostate specific membrane antigen (PSMA): A neurocarboxypeptidase and membrane folate hydrolase;Bedeutung des prostataspezifischen Membranantigens (PSMA). Eine Neurocarboxypeptidase und Membran-Folat-Hydrolase

Urologe - Ausgabe A

Volumn 35, Issue 5, 1996, Pages 400-407

  Heston, W D W ^a,b  

^a George M O'Brien Urology Research Center   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

folate hydrolase; neurocarboxypeptidase; prostate specific membrane antigen; RT PCR

Indexed keywords

TUMOR MARKER;

HUMAN; MALE; PROSTATE CANCER; REVIEW;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BASE SEQUENCE; CLONING, MOLECULAR; DIPEPTIDASES; DNA, COMPLEMENTARY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RECEPTORS, TRANSFERRIN; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 0029789975     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050041     Document Type: Review

References (17)

1. Horosczewicz JS, Leong SS, Kawinski E et al. (1991) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818
2. Horosczewicz JS, Kawinski E, Murphy JP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7: 927-936
3. Israeli R, Powell CT, Fair W, Heston WNW (1993) Molecular cloning of a complimentary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227-230
4. Su S, Fair W, Powell CT, Heston WNW (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 55: 1441-1443
5. Troyer J, Fang Q, Beckett ML, Wright Jr GL (1995) Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate specific membrane antigen. Urol Oncol 1: 29-37
6. Carter RE, Feldman AR, Coyle JT (1996) Prostate-specific membrane antigen is a hydolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Nat Acad Sci 93: 749-753
7. Heston WDW, Silver DA, Pellicer I, Fair WR, Cordon-Cardo C (1996) Ionotropic glutamate receptor distribution in prostate tissue. J Urol A: 156
8. Dionne CA, Camorretto A, Jani J et al. (1996) The TRK tyrosine kinase inhibitor, CEP-751 (KT-6587) inhibits prostate cancer growth. Keystone Symposia on Breast and Prostate Cancer: Basic Mechanisms. (Abst # 7)
9. Papandreou P, Freeman R, Xu Y, Scheinberg D, Maslak P, Scher HI (1996) Neutral endopeptidase regulation by androgen in prostate cancer cells. Proc Am Assoc Cancer Res 37: 244
10. Troyer JK, Beckett ML, Wright Jr GL (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-558
11. Pinto J, Suffoletto B, May F et al. (1996) Identification of a membrane bound pteroyl gamma-glutamyl carboxypeptidase (folate hydrolase) that is highly expressed in human prostatic carcinoma cells. Clin Cancer Res (in press)
12. Heston WDW (1991) Prostatic polyamines and polyamine targeting as a new aproach to the therapy of prostatic cancer. Cancer Surv 11: 217-238
13. Jarrard DF, Bova GS, Isaacs WB (1996) DNA methylation, molecular genetic and linkage studies in prostate cancer. Prostate 6: 36-44
14. Warren DW, Heston (1995) Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate specific membrane antigen. Clin Chem 41: 1687-1688
15. Su SL, Heston WDW, Perotti M et al. (1996) Evaluating the effectiveness of neo-adjuvant therapy on systemic disease: Use of RT-PCR. Urology (in press)
16. Loric S, Dumas F, Eschewege P, Blanchet P, Benoit G, Jardin A, Lacour B (1995) Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 41: 1698-1704
17. Eschwege P, Dumas F, Blanchet P et al. (1995) Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346: 1528-1530